--- title: "Akanda Corp. Delays 20-F Amid Strategic Shift" type: "News" locale: "en" url: "https://longbridge.com/en/news/284929092.md" description: "Akanda Corp. (AKAN) has announced a delay in filing its Annual Report on Form 20-F for the financial year ending December 31, 2025, due to complexities from operational changes, including the liquidation of its Canmart business and the acquisition of First Towers & Fiber Corp. The company reported revenues of approximately $258,075 for 2025, an increase from zero in 2024, despite higher operating expenses of about $4.83 million. Akanda aims to file the report within 15 days of the original SEC deadline, maintaining compliance with U.S. securities regulations." datetime: "2026-05-01T18:17:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284929092.md) - [en](https://longbridge.com/en/news/284929092.md) - [zh-HK](https://longbridge.com/zh-HK/news/284929092.md) --- # Akanda Corp. Delays 20-F Amid Strategic Shift Akanda Corp ( (AKAN) ) has released a notification of late filing. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Akanda Corp. has filed a Form 12b-25 indicating a delay in submitting its Annual Report on Form 20-F (Yearly Report) for the financial year ended December 31, 2025. The company says it could not compile all required disclosure information in time without incurring unreasonable effort or expense, prompting the late filing notice. Management attributes the delay primarily to the complexity of preparing its year-end disclosures following significant changes in operations and structure. These include the liquidation of its Canmart business in the U.K. and the acquisition of First Towers & Fiber Corp., which together require extensive legal, accounting and disclosure work. Akanda Corp. has committed to filing its Form 20-F (Yearly Report) no later than the fifteenth calendar day after the original SEC deadline. Investors should therefore expect the overdue annual report to be submitted within this grace period, assuming no further complications arise. The company has signaled a major change in its financial profile, with revenues of about $258,075 for 2025 versus zero revenue in 2024, driven by leasing fiber networks and telecom towers in Mexico. Despite higher operating expenses of roughly $4.83 million in 2025, the net loss improved to around $3.76 million from $4.10 million a year earlier, though these figures remain subject to final reporting and forward-looking uncertainties. Akanda notes that operating expenses rose mainly due to legal, audit, accounting and consulting fees tied to SEC compliance, plus higher depreciation and amortization linked to new infrastructure assets. These details point to a business in transition, investing heavily in governance and telecom growth while still operating at a loss. The company affirms that all other required periodic reports have been filed on time, indicating efforts to remain in good standing with U.S. securities regulators. The notification is signed by Interim Chief Executive Officer and Director Katie Field on May 1, 2026, underscoring management’s formal commitment to complete the Form 20-F (Yearly Report) and maintain regulatory compliance. **More about Akanda Corp** Akanda Corp. is an international company that has shifted its focus from cannabis operations in the U.K. to telecommunications infrastructure. The company recently liquidated its Canmart business and now generates revenue through First Towers & Fiber Corp., which develops and leases fiber optic networks and telecom towers in Mexico. **Average Trading Volume:** 1,961,544 **Technical Sentiment Signal:** Sell **Current Market Cap:** $26.16M ### Related Stocks - [AKAN.US](https://longbridge.com/en/quote/AKAN.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md) - [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md) - [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md) - [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md) - [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)